AUG 25, 2020 10:25 AM PDT

FDA Approves Cannabis Drug to Treat Rare Genetic Disease

WRITTEN BY: Annie Lennon

The US Food and Drug Administration has approved Epidiolex, a cannabidiol (CBD) oral solution, to treat seizures linked to tuberous sclerosis complex (TSC), a rare genetic disease that causes benign tumors to grow on the brain and other organs such as the eyes, heart, and lungs.

Occurring in around 1 in 6,000 people, TSC typically affects the central nervous system. Aside from seizures, it is also known to cause developmental delay and behavioral problems. 

Previously, Epidolex had been approved to treat seizures from two rare forms of epilepsy: Lennox-Gestaut syndrome (LGS) and Dravet syndrome (DS). It is also currently the only FDA-approved drug to contain a purified substance derived from cannabis.

Prior to approval, Epidolex underwent a randomized, double-blind, placebo-controlled trial where 148 patients out of 224 received the drug. The purpose of the study was to measure the difference from baseline in seizure frequency. 

In the end, the researchers found that patients treated with Epidolex had a significant reduction in the frequency of seizures during the treatment periods than those on the placebo. The effects were seen within eight weeks and remained throughout the 16-week treatment period. 

The most common side effects form the drug in patients with TSC included diarrhea, elevated liver enzymes, decreased appetite, fever, sleepiness, and vomiting. Less common side effects for patients, regardless of condition, include liver injury, reduced weight, anemia, and increased creatinine, a sign of impaired kidney function.  

Given its potential for negative side effects (findings from a human trial showing that between 5% and 20% of patients receiving the drug suffered from liver damage), extreme care is needed for those who take it. As such, after prescription by a physician, parents, caregivers, and families are advised to monitor any unusual changes in mood or behavior, including worsening depression and suicidal thoughts, among those taking the drug. 

 

Sources: LabRootsMedical News

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
AUG 22, 2020
Cannabis Sciences
People with Depression Twice as Likely to Use Cannabis
AUG 22, 2020
People with Depression Twice as Likely to Use Cannabis
Researchers from Columbia University have found that people with depression are around twice as likely to use cannabis t ...
SEP 09, 2020
Health & Medicine
Cannabis Legalization Not Linked With Pedestrian Deaths
SEP 09, 2020
Cannabis Legalization Not Linked With Pedestrian Deaths
Changes in cannabis legalization status haven’t caused an uptick in pedestrians being killed by cars, a study has ...
OCT 14, 2020
Health & Medicine
Sanobiotec Produces Reliable THCV
OCT 14, 2020
Sanobiotec Produces Reliable THCV
Lithuania-based bio Sanobiotec has joined a band of biotech companies moving into the synthetic cannabinoid market and a ...
NOV 06, 2020
Health & Medicine
Cannabis Help for Fibromyalgia
NOV 06, 2020
Cannabis Help for Fibromyalgia
Fibromyalgia is a debilitating condition with a spectrum of symptoms that include pervasive musculoskeletal pain accompa ...
DEC 11, 2020
Health & Medicine
Cannabis Consumers Clueless About the Strength of Their Products
DEC 11, 2020
Cannabis Consumers Clueless About the Strength of Their Products
Cannabis consumers aren’t clued up on the THC:CBD ratios of the products they use a study has found. That's re ...
JAN 13, 2021
Cannabis Sciences
Cannabis and Tobacco Smoke Contain Same Toxins
JAN 13, 2021
Cannabis and Tobacco Smoke Contain Same Toxins
Cannabis and tobacco smoke are known to share some of the same toxins. Now, researchers from Dana-Farber Cancer Institut ...
Loading Comments...